In the fourth quarter of 2024, 95 economic entities filed for bankruptcy in Poland, a three percent decrease from the previous year's corresponding period. Most of these cases occurred in the industry sector.

According to a survey fielded in Mexico in ***********, ** percent of respondents stated having to close their businesses as a result of the COVID-19 pandemic. This represents a noticeable decrease compared to April, when ** percent of participants said they had to shut down their businesses.

As of May 31, 2024, the number of bankruptcies in Japan directly related to the impact of the coronavirus disease (COVID-19) amounted to ***** cases in Tokyo Prefecture. In total, around *** thousand business enterprises in the country went bankrupt due to COVID-19.

This dataset is no longer being updated as of 7/1/2021. It is being retained on the Open Data Portal for its potential historical interest.

A list of retail stores, restaurants, personal services and other businesses open and closed during the COVID-19 pandemic. Also indicates if business is offering delivery, pick up or on-line sales.

Updated at least biweekly during Covid-19 Pandemic.

During an online survey, *** percent of surveyed small businesses in the United States said they had temporarily closed a location due to the COVID-19 pandemic during the week ending April 17, 2022. Another *** percent of respondents said that they had opened a previously closed location during the same week.

COVID-19 Economic Injury Disaster Loans as of 12-01-20. More recent data can be found on USAspending.gov.

This dataset consolidates public U.S. Small Business Administration (SBA) Economic Injury Disaster Loan (EIDL) data released during the COVID-19 pandemic.

It contains loan-level records issued between April and November 2020, documenting the scale and timing of emergency relief for small businesses across all U.S. states and territories.

The files were retrieved from the SBA’s open-data portal and standardized for analysis in Python (Pandas) and visualization in Tableau.

Fields include: • Loan amount (face value or obligation) • Approval date • State of recipient • Recipient identifier

Analytical use: This data supports exploration of post-COVID economic recovery patterns, showing how federal loan programs helped stabilize small businesses by region and time period.

Source: U.S. Small Business Administration Open Data

Last updated: November 2020

Prepared by: Christopher White (@cwhiteprofessional)

License: U.S. Government Works — This dataset is derived from public SBA data and is not subject to copyright protection under 17 U.S.C. §105. It may be freely reused and shared.

Almost one quarter of all businesses have temporarily closed or paused trading due to the Coronavirus (COVID-19) pandemic in the United Kingdom as of April 2020. The sector with the highest share of business closures were those in the arts, entertainment, and recreation sector, with over ** percent of them currently closed, compared with just *** percent of human health, and social work businesses.

The aim of the special survey of the GESIS panel on the outbreak of the corona virus SARS-CoV-2 in Germany was to collect timely data on the effects of the corona crisis on people´s daily lives. The study focused on questions of risk perception, risk minimization measures, evaluation of political measures and their compliance, trust in politics and institutions, changed employment situation, childcare obligations, and media consumption. Due to the need for timely data collection, only the GESIS panel sub-sample of online respondents was invited (about three quarters of the sample). Since, due to time constraints, respondents could only participate in the online survey but not by mail, the results cannot be easily transferred to the overall population. Further longitudinal surveys on Covid-19 with the entire sample of the GESIS panel are planned for 2020.

Topics: Risk perception: Probability of events related to corona infection in the next two months (self, infection of a person from close social surrondings, hospital treatment, quarantine measures regardless of whether infected or not, infecting other people)

Risk minimization: risk minimization measures taken in the last seven days (avoided certain (busy) places, kept minimum distance to other people, adapted school or work situation, quarantine due to symptoms or without symptoms, washed hands more often, used disinfectant, stocks increased, reduced social interactions, worn face mask, other, none of these measures).

Evaluation of the effectiveness of various policy measures to combat the further spread of corona virus (closure of day-care centres, kindergartens and schools, closure of sports facilities, closure of bars, cafés and restaurants, closure of all shops except supermarkets and pharmacies, ban on visiting hospitals, nursing homes and old people´s homes, curfew for persons aged 70 and over or people with health problems or for anyone not working in the health sector or other critical professions (except for basic purchases and urgent medical care).

Curfew compliance or refusal: Willingness to obey a curfew vs. refusal; reasons for the compliance with curfew (social duty, fear of punishment, protection against infection, fear of infecting others (loved ones, infecting others in general, a risk group); reasons for refusal of curfew (restrictions too drastic or not justified, other obligations, does not stop the spread, not affected by the outbreak, boring at home, will not be punished).

Evaluation of the effectiveness of various government measures (medical care, restrictions on social life such as closure of public facilities and businesses, reduction of economic damage, communication with the population).

Trust in politics and institutions with regard to dealing with the coronavirus (physician, local health authority, local and municipal administration, Robert Koch Institute (RKI), Federal Government, German Chancellor, Ministry of Health, World Health Organization (WHO), scientists).

Changed employment situation: employment status at the beginning of March; change in occupational situation since the spread of coronavirus: dependent employees: number of hours reduced, number of hours increased, more home office, leave of absence with/ without continued wage payment , fired, no change; self-employed: working hours reduced, working hours increased, more home office, revenue decreased, revenue increased, company temporarily closed by the authorities, company temporarily voluntarily closed, financial hardship, company permanently closed or insolvent, no change.

Childcare: children under 12 in the household; organisation of childcare during the closure of day-care centres, kindergartens and schools (staying at home, partner stays at home, older siblings take care, grandparents are watching, etc.)

Media consumption on Corona: information sources used for Corona (e.g. nationwide public or private television or radio, local public or private television or radio, national newspapers or local newspapers, Facebook, other social media, personal conversations with friends and family, other, do not inform myself on the subject); frequency of Facebook usage; information about Corona obtained from regional Facebook page or regional Facebook group.

Demography: sex; age (categorized); education (categorized); intention to vote and choice of party (Sunday question); Left-right self-assessment; marital status; size of household.

Additionally coded: Respondent ID;...

Local authorities have received and distributed funding to support small and medium businesses in England during coronavirus. The datasets cover schemes managed by local authorities: Additional Restrictions Support Grant (ARG) Restart Grant - closed June 2021 Local Restrictions Support Grants (LRSG) and Christmas support payments - closed 2021 Small Business Grants Fund (SBGF) - closed August 2020 Retail, Hospitality and Leisure Business Grants Fund (RHLGF) - closed August 2020 Local Authority Discretionary Grants Fund (LADGF) - closed August 2020 The spreadsheets show the total amount of money that each local authority in England: received from central government distributed to SMEs 20 December 2021 update We have published the latest estimates by local authorities for payments made under this grant programme: Additional Restrictions Grants (up to and including 28 November 2021) The number of grants paid out is not necessarily the same as the number of businesses paid. The data has not received full verification.

The Paycheck Protection Program (PPP) is a nearly $1 trillion business loan program started in 2020 under the Trump administration to provide relief to businesses struggling due to the Coronavirus epidemic.

This program that was managed by the Small Business Administration (SBA) offers loans to companies based on current payroll expense. The exact amount a business qualifies for depends on a number of factors including corporate structure, but generally follows the guidelines below:

Average monthly payroll (using a maximum annual salary per employee of $100,000) * 2.5

in 2020, a judge ordered the SBA to release all data on PPP loans, even those loans made for less than $150,000.

This dataset represents only businesses who received loans of more than $150,000, and presents an interesting opportunity for researchers in the data science community. Some potential projects are listed below: - Exploring loan amounts industries and business types - Using this data as features to predict business metrics such as company size, revenue, risk of bankruptcy. - Tracking important demographic statistics related to loan amounts and any potential bias in the program.

Snapshot img { margin: 10px !important; } This pipeline analysis report provides detailed insights into the clinical trials landscape of COVID-19 therapeutics, including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration (RoA), target, mechanism of action (MoA), and therapeutic modalities. Furthermore, the report provides an analysis of the companies currently involved in the development of pipeline molecules for COVID-19 including AbbVie Inc., AIM ImmunoTech Inc., Ansun BioPharma, APEIRON Biologics AG, Ascletis Pharma Inc., Blade Therapeutics Inc., Can-Fite BioPharma Ltd., CanSino Biologics Inc., Clover Biopharmaceuticals, F. Hoffmann-La Roche Ltd., FUJIFILM Corp., Gilead Sciences Inc., IMV Inc., InflaRx GmbH, Inovio Pharmaceuticals Inc., and Johnson & Johnson Services Inc.

Overview of Therapeutic Pipeline for COVID-19

The COVID-19 pandemic started in China in the last quarter of 2019 and spread globally by early 2020. Globally, the incidence and prevalence of COVID-19 are increasing aggressively. According to the Worldometers.info report, updated on April 13, 2020, the number of COVID-19 cases reported was 1,862,254, out of which 6.17% of the people have lost their lives, and about 23.18% people have been recovered globally.

Coronavirus disease (COVID-19) is infectious and is caused by a new coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the people affected with COVID-19 experience mild-to-moderate respiratory illness and recover without requiring special treatment. However, older people and people with certain medical conditions, including cardiovascular diseases, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness. Currently, there are no specific vaccines or treatments for COVID-19. However, owing to the above-mentioned factors, many ongoing clinical trials are evaluating potential treatments, especially target molecules for the immune system. Over 26% of the molecules in the pipeline are currently in the pre-clinical stages.

Companies covered

Several companies are involved in the development of pipeline molecules for COVID-19. In addition to the companies, major institutes, universities, and hospitals are also conducting studies on COVID-19. Moreover, companies are collaborating with institutions such as the US Department of Health & Human Services and the University of British Columbia to use the available technologies properly for the further development and commercialization of molecules.

The report covers detailed information on several companies actively involved in the development of molecules for COVID-19 including -

AbbVie Inc.
AIM ImmunoTech Inc.
Ansun BioPharma
APEIRON Biologics AG
Ascletis Pharma Inc.
Blade Therapeutics Inc.
Can-Fite BioPharma Ltd.
CanSino Biologics Inc.
Clover Biopharmaceuticals
F. Hoffmann-La Roche Ltd.
FUJIFILM Corp.
Gilead Sciences Inc.
IMV Inc.
InflaRx GmbH
Inovio Pharmaceuticals Inc.
Johnson & Johnson Services Inc.
Mallinckrodt Plc
Moderna Inc.
NeuroRx Inc.
Novavax Inc.
OncoImmune Inc.
OyaGen Inc.
Pulmotect Inc.
RedHill Biopharma Ltd.
Regeneron Pharmaceuticals Inc.
Sanofi
SLA Pharma AG
Sorrento Therapeutics Inc.
Swedish Orphan Biovitrum AB
Symvivo Corp.
Takeda Pharmaceutical Co.
Tonix Pharmaceuticals Holding Corp.
Vanda Pharmaceuticals Inc.
Vaxart Inc.

COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Route of Administration

Oral
Intravenous
Nasal
Intradermal
Intramuscular
Unknown

Most of the pipeline molecules for COVID-19 treatment are being developed for oral administration. Additionally, companies and institutions are also focusing on developing drugs that can be delivered through the subcutis (intravenous RoA).

COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Therapy

Monotherapy
Combination therapy

Monotherapy uses a single drug to treat a disorder. Over 64% of the molecules that are currently in the pipeline to treat COVID-19 are being developed as monotherapy drugs.

COVID-19 - Pipeline Analysis: Key Highlights of the Report

What are the therapy molecules used in the various development stages of COVID-19?
What are the companies that are currently involved in the development of therapeutic molecules for COVID-19?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule

We can help! Our analysts can customize this report to meet your requirements. Get in touch

The Paycheck Protection Program (PPP) is a $953-billion business loan program established by the United States federal government, led by the Donald Trump administration in 2020 through the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) to help certain businesses, self-employed workers, sole proprietors, certain non-profit organizations, and tribal businesses continue paying their workers.

The Paycheck Protection Program allows entities to apply for low-interest private loans to pay for their payroll and certain other costs. The amount of a PPP loan is approximately equal to 2.5 times the applicant's average monthly payroll costs. In some cases, an applicant may receive a second draw typically equal to the first. The loan proceeds may be used to cover payroll costs, rent, interest, and utilities. The loan may be partially or fully forgiven if the business keeps its employee counts and employee wages stable. The program is implemented by the U.S. Small Business Administration. The deadline to apply for a PPP loan was March 31, 2021.

Some economists have found that the PPP did not save as many jobs as purported and aided too many businesses that were not at risk of going under. They noted that other programs, such as unemployment insurance, food assistance, and aid to state and local governments, would have been more efficient at strengthening the economy. Opponents to this view note that the PPP functioned well to prevent business closures and cannot be measured on the number of jobs saved alone.

According to a 2022 study, the PPP: cumulatively preserved between 2 and 3 million job-years of employment over 14 months at a cost of $169K to $258K per job-year retained. These numbers imply that only 23 to 34 percent of PPP dollars went directly to workers who would otherwise have lost jobs; the balance flowed to business owners and shareholders, including creditors and suppliers of PPP-receiving firms. Program incidence was ultimately highly regressive, with about three-quarters of PPP funds accruing to the top quintile of households. PPP's breakneck scale-up, its high cost per job saved, and its regressive incidence have a common origin: PPP was essentially untargeted because the United States lacked the administrative infrastructure to do otherwise. Harnessing modern administrative systems, other high-income countries were able to better target pandemic business aid to firms in financial distress. Building similar capacity in the U.S. would enable improved targeting when the next pandemic or other large-scale economic emergency inevitably arises.

Additional Information Field: Value Created: April 5, 2022 Format: CSV License: Other (Public Domain) Size: 428.6 MiB

Companies in the arts, entertainment and recreation sector have had to shut down their activity the most, since the beginning of the coronavirus crisis (COVID-19). Companies in this sector have been closed for an average of almost 100 days. The hotel industry was the second sector most affected by closures. The pharmaceutical industry was the least affected by closures. On average, French companies were closed for ** days in France.

Snapshot img

Covid-19 Vaccination Market 2024-2028

The covid-19 vaccination market size is forecast to increase by USD -32.76 billion, at a CAGR of -37.4% between 2023 and 2028. The market is experiencing significant growth due to the expansion of vaccination programs worldwide. Governments and international organizations are investing heavily in vaccination initiatives to contain the spread of the virus. The rising research and development (R&D) investment in the development of Covid-19 vaccines is another major growth factor. However, the high cost of production of Covid-19 vaccines poses a significant challenge to market growth. Manufacturers are exploring various strategies to reduce production costs while maintaining vaccine efficacy and safety. The market is expected to witness strong growth in the coming years as more effective and affordable vaccines become available. poiuyfrtyh

What will the Covid-19 Vaccination Market Size be During the Forecast Period?

Download Report Sample to Unlock the Covid-19 Vaccination Market Size for the Forecast Period and Other Important Statistics

Market Dynamics

The COVID-19 pandemic has brought about an unprecedented global health crisis, leading to the development of numerous vaccines to mitigate its impact. This content focuses on various aspects of COVID-19 vaccines, including production, distribution, administration, efficacy, safety, and regulations. COVID-19 vaccine production has been a top priority for researchers and pharmaceutical companies worldwide. Several manufacturers have developed vaccines using various technologies such as mRNA, viral vector, and protein subunit, undergoing rigorous testing and clinical trials to ensure safety and efficacy. Once vaccines receive approval from regulatory bodies, they are distributed to healthcare facilities and vaccination centers, requiring careful planning and coordination. Governments and international organizations are working to ensure equitable distribution, prioritizing vulnerable populations and herd immunity. Vaccine administration involves healthcare professionals delivering vaccines through injections, with proper training and safety protocols to minimize adverse reactions. Efficacy refers to the vaccine's ability to prevent infection or reduce the severity of symptoms, with most vaccines showing high efficacy rates, ranging from 60% to 95%. Vaccine safety is monitored closely, and while common side effects include pain and swelling at the injection site, fever, and fatigue, serious side effects are rare.

Vaccine procurement involves purchasing vaccines from manufacturers, with governments securing supplies through contracts and partnerships. Vaccine allocation ensures that vaccines are distributed to specific populations, with priority given to vulnerable groups like healthcare workers and the elderly. Vaccine prioritization determines which populations should receive vaccines first, based on risk factors. Vaccine passports are digital or physical documents that prove vaccination status, and may be required for travel or work, with regulations varying by jurisdiction. Vaccine mandates, which require vaccination for employment or participation in certain activities, remain a controversial issue. Vaccine regulations ensure vaccines are safe and effective, and policies governing vaccine use in schools, workplaces, and travel may change as supplies and public health conditions evolve.

Covid-19 Vaccination Market Driver

The expansion of vaccination programs is the key driver of the market. The market is experiencing significant growth due to the increasing demand for vaccines as governments and healthcare organizations prioritize widespread vaccination to control the virus and achieve herd immunity. This heightened demand leads to increased production and sales for vaccine manufacturers, resulting in long-term procurement contracts being signed to ensure a consistent vaccine supply. These contracts provide stability and revenue for manufacturers, with more contracts expected to be established as vaccination programs expand.

Vaccine distribution, administration, and logistics are crucial elements in the vaccine market, requiring efficient vaccine storage, transportation, and scheduling. Vaccine safety, efficacy, and monitoring are also vital considerations, along with addressing vaccine hesitancy and acceptance through education and outreach efforts. Vaccine regulations, policies, and campaigns are essential in ensuring vaccine coverage, immunity, and compliance with side effects and potential mandates or certificates.

Covid-19 Vaccination Market Trends

Rising research and development investment is the upcoming trend in the market. The Covid-19 pandemic has necessitated the rapid development, production, and distribution of vaccines to prevent and treat the disease caused by the SARS-CoV-2 virus. Governments and the private sector have collaborated to invest in vacc

The global vaccine market, including COVID-19 vaccines, is a dynamic and rapidly evolving sector. With a 2025 market size of $58,060 million and a projected Compound Annual Growth Rate (CAGR) of 3.7% from 2025 to 2033, significant growth is anticipated. This expansion is driven by several factors, including rising prevalence of vaccine-preventable diseases, increasing government initiatives promoting vaccination programs, and advancements in vaccine technology leading to the development of more effective and safer vaccines. The COVID-19 pandemic significantly accelerated vaccine development and deployment, boosting market growth and highlighting the crucial role of vaccines in public health. However, challenges remain, including vaccine hesitancy, the high cost of vaccine development and distribution, and the need for continuous research and development to combat emerging infectious diseases and adapt to evolving viral strains. The market is highly competitive, with major players like Pfizer, Sanofi, AstraZeneca, and several prominent Chinese and Indian manufacturers vying for market share. Future growth will likely be influenced by the success of new vaccine candidates, the effectiveness of ongoing vaccination campaigns, and the emergence of new pandemic threats. The market is segmented based on vaccine type (live attenuated, inactivated, etc.), disease indication (influenza, measles, COVID-19, etc.), and route of administration. Geographical variations in vaccination rates and healthcare infrastructure will also influence regional market performance. The competitive landscape is characterized by a mix of established pharmaceutical giants and emerging biotechnology companies. Strategic partnerships, mergers and acquisitions, and continuous innovation are shaping the market dynamics. The increasing focus on personalized medicine and the development of next-generation vaccines, such as mRNA vaccines and gene-based vaccines, offer significant growth opportunities. However, regulatory hurdles and the stringent safety requirements associated with vaccine development pose significant challenges. To further fuel growth, companies are investing heavily in R&D to develop novel vaccines with improved efficacy, safety profiles, and ease of administration. This includes advancements in delivery systems like needle-free options and the exploration of combination vaccines to reduce the number of injections needed. Furthermore, global collaborations and investments in vaccine manufacturing capacity are crucial to ensure equitable access to vaccines worldwide.

What is the COVID-19 Economic Vulnerability Index?The COVID-19 Vulnerability Index (CVI) is a measurement of the negative impact that the coronavirus (COVID-19) crisis can have on employment based upon a region's mix of industries. For example, accommodation and food services are projected to lose more jobs as a result of the coronavirus (in the neighborhood of 50%) compared with utilities and healthcare (with none or little expected job contraction).This updated dataset contains 116 jobs attributes including the 10 most likely jobs to be impacted for each county, the total employment and employment by sector. An attribute list is included below.An average Vulnerability Index score is 100, representing the average job loss expected in the United States. Higher scores indicate the degree to which job losses may be greater — an index score of 200, for example, means the rate of job loss can be twice as large as the national average. Conversely, an index score of 50 would mean a possible job loss of half the national average. Regions heavily dependent on tourism with relatively high concentrations of leisure and hospitality jobs, for example, are likely to have high index scores. The Vulnerability Index only measures the impact potential related to the mix of industry employment. The index does not take into account variation due to a region’s rate of virus infection, nor does it factor in local government's policies in reaction to the virus. For more detail, please see this description.MethodologyThe index is based on a model of potential job losses due to the COVID-19 outbreak in the United States. Expected employment losses at the subsector level are based upon inputs which include primary research on expert testimony; news reports for key industries such as hotels, restaurants, retail, and transportation; preliminary release of unemployment claims; and the latest job postings data from Chmura's RTI database. The forecast model, based on conditions as of March 23, 2020, assumes employment in industries in each county/region would change at a similar rate as employment in national industries. The projection estimates that the United States could lose 15.0 million jobs due to COVID-19, with over half of the jobs lost in hotels, food services, and entertainment industries. Contact Chmura for further details.Attribute ListFIPSCounty NameStateTotal JobsWhite Collar JobsBlue Collar JobsService JobsWhite Collar %Blue Collar %Service %Government JobsGovernment %Primarily Self-Employed JobsPrimarily Self-Employed %Job Change, Last Ten YearsIndustry 1 NameIndustry 1 EmplIndustry 1 %Industry 2 NameIndustry 2 EmplIndustry 2 %Industry 3 NameIndustry 3 EmplIndustry 3 %Industry 4 NameIndustry 4 EmplIndustry 4 %Industry 5 NameIndustry 5 EmplIndustry 5 %Industry 6 NameIndustry 6 EmplIndustry 6 %Industry 7 NameIndustry 7 EmplIndustry 7 %Industry 8 NameIndustry 8 EmplIndustry 8 %Industry 9 NameIndustry 9 EmplIndustry 9 %Industry 10 NameIndustry 10 EmplIndustry 10 %All Other IndustriesAll Other Industries EmplAll Other Industies %Agriculture, Food & Natural Resources EmplArchitecture and Construction EmplArts, A/V Technology & Communications EmplBusiness, Management & Administration EmplEducation & Training EmplFinance EmplGovernment & Public Administration EmplHealth Science EmplHospitality & Tourism EmplHuman Services EmplInformation Technology EmplLaw, Public Safety, Corrections & Security EmplManufacturing EmplMarketing, Sales & Service EmplScience, Technology, Engineering & Mathematics EmplTransportation, Distribution & Logistics EmplAgriculture, Food & Natural Resources %Architecture and Construction %Arts, A/V Technology & Communications %Business, Management & Administration %Education & Training %Finance %Government & Public Administration %Health Science %Hospitality & Tourism %Human Services %Information Technology %Law, Public Safety, Corrections & Security %Manufacturing %Marketing, Sales & Service %Science, Technology, Engineering & Mathematics %Transportation, Distribution & Logistics %COVID-19 Vulnerability IndexAverage Wages per WorkerAvg Wages Growth, Last Ten YearsUnemployment RateUnderemployment RatePrime-Age Labor Force Participation RateSkilled Career 1Skilled Career 1 EmplSkilled Career 1 Avg Ann WagesSkilled Career 2Skilled Career 2 EmplSkilled Career 2 Avg Ann WagesSkilled Career 3Skilled Career 3 EmplSkilled Career 3 Avg Ann WagesSkilled Career 4Skilled Career 4 EmplSkilled Career 4 Avg Ann WagesSkilled Career 5Skilled Career 5 EmplSkilled Career 5 Avg Ann WagesSkilled Career 6Skilled Career 6 EmplSkilled Career 6 Avg Ann WagesSkilled Career 7Skilled Career 7 EmplSkilled Career 7 Avg Ann WagesSkilled Career 8Skilled Career 8 EmplSkilled Career 8 Avg Ann WagesSkilled Career 9Skilled Career 9 EmplSkilled Career 9 Avg Ann WagesSkilled Career 10Skilled Career 10 EmplSkilled Career 10 Avg Ann Wages